{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:07:34Z","timestamp":1740179254120,"version":"3.37.3"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":158,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Many bacterial polysaccharide vaccines, including the typhoid Vi polysaccharide (ViPS) and tetravalent meningococcal polysaccharide conjugate (MCV4) vaccines, do not incorporate adjuvants and are not highly immunogenic, particularly in infants. I found that endotoxin, a TLR4 ligand in ViPS, contributes to the immunogenicity of typhoid vaccines. Because endotoxin is pyrogenic, and its levels are highly variable in vaccines, I developed monophosphoryl lipid A, a nontoxic TLR4 ligand\u2013based adjuvant named Turbo. Admixing Turbo with ViPS and MCV4 vaccines improved their immunogenicity across all ages and eliminated booster requirement. To understand the characteristics of this adjuvanticity, I compared Turbo with alum. Unlike alum, which polarizes the response toward the IgG1 isotype, Turbo promoted Ab class switching to all IgG isotypes with affinity maturation; the magnitude of this IgG response is durable and accompanied by the presence of long-lived plasma cells in the mouse bone marrow. In striking contrast with the pathways employed by alum, Turbo adjuvanticity is independent of NLPR3, pyroptotic cell death effector Gasdermin D, and canonical and noncanonical inflammasome activation mediated by Caspase-1 and Caspase-11, respectively. Turbo adjuvanticity is primarily dependent on the MyD88 axis and is lost in mice deficient in costimulatory molecules CD86 and CD40, indicating that Turbo adjuvanticity includes activation of these pathways. Because Turbo formulations containing either monophosphoryl lipid A or TLR2 ligands, Pam2CysSerLys4, and Pam3CysSerLys4 help generate Ab response of all IgG isotypes, as an adjuvant Turbo can improve the immunogenicity of glycoconjugate vaccines against a wide range of bacterial pathogens whose elimination requires appropriate IgG isotypes.<\/jats:p>","DOI":"10.4049\/immunohorizons.2400040","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T13:57:47Z","timestamp":1722607067000},"page":"527-537","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of Turbo, a TLR Ligand-based Adjuvant for Glycoconjugate Vaccines"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8092-514X","authenticated-orcid":false,"given":"Kishore R","family":"Alugupalli","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA"},{"name":"TurboVax Inc. , Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"2025010608555275000_r1","doi-asserted-by":"crossref","first-page":"808005","DOI":"10.3389\/fcimb.2021.808005","article-title":"Immunobiology of carbohydrates: implications for novel vaccine and adjuvant design against infectious diseases","volume":"11","author":"Stefanetti","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"2025010608555275000_r2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"year":"2008","author":"Levine","key":"2025010608555275000_r3"},{"key":"2025010608555275000_r4","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and efficacy of a typhoid conjugate vaccine in Malawian children","volume":"385","author":"Patel","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025010608555275000_r5","doi-asserted-by":"crossref","first-page":"e1561","DOI":"10.1016\/S2214-109X(21)00346-6","article-title":"Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial","volume":"9","author":"Shakya","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"2025010608555275000_r6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri","year":"2021","journal-title":"Lancet"},{"key":"2025010608555275000_r7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"2025010608555275000_r8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O\u2019Brien","year":"2009","journal-title":"Lancet"},{"key":"2025010608555275000_r9","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/pathogens12050732","article-title":"Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults","volume":"12","author":"Farrar","year":"2023","journal-title":"Pathogens"},{"key":"2025010608555275000_r10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/vaccines8020304","article-title":"Technological approaches for improving vaccination compliance and coverage","volume":"8","author":"Lemoine","year":"2020","journal-title":"Vaccines. (Basel)"},{"key":"2025010608555275000_r11","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1097\/INF.0000000000000076","article-title":"Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers","volume":"33","author":"Whitney","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"2025010608555275000_r12","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.4049\/jimmunol.175.5.3084","article-title":"In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands","volume":"175","author":"Sen","year":"2005","journal-title":"J. Immunol."},{"key":"2025010608555275000_r13","doi-asserted-by":"crossref","first-page":"e0128656","DOI":"10.1371\/journal.pone.0128656","article-title":"Vaccination coverage and compliance with three recommended schedules of 10-valent pneumococcal conjugate vaccine during the first year of its introduction in Brazil: a cross-sectional study","volume":"10","author":"Saraiva","year":"2015","journal-title":"PLoS One"},{"key":"2025010608555275000_r14","first-page":"187","volume-title":"Reproductive, Maternal, Newborn, and Child Health: Disease Control Priorities","author":"Feikin","year":"2016","edition":"3rd Ed."},{"key":"2025010608555275000_r15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/SQB.1989.054.01.003","article-title":"Approaching the asymptote? Evolution and revolution in immunology","volume":"54","author":"Janeway","year":"1989","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"2025010608555275000_r16","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1128\/IAI.67.12.6375-6384.1999","article-title":"Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines","volume":"67","author":"Guttormsen","year":"1999","journal-title":"Infect. Immun."},{"key":"2025010608555275000_r17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"2025010608555275000_r18","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.4049\/jimmunol.178.6.3740","article-title":"MyD88- and Bruton\u2019s tyrosine kinase-mediated signals are essential for T cell-independent pathogen-specific IgM responses","volume":"178","author":"Alugupalli","year":"2007","journal-title":"J. Immunol."},{"key":"2025010608555275000_r19","first-page":"105","article-title":"A distinct role for B1b lymphocytes in T cell-independent immunity","volume":"319","author":"Alugupalli","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2025010608555275000_r20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4049\/immunohorizons.2300085","article-title":"TLR4 ligands in typhoid vi polysaccharide subunit vaccines contribute to immunogenicity","volume":"8","author":"Alugupalli","year":"2024","journal-title":"Immunohorizons"},{"key":"2025010608555275000_r21","first-page":"58","article-title":"Endotoxin content in Haemophilus influenzae type b vaccine","volume":"57","author":"Ochiai","year":"2004","journal-title":"Jpn. J. Infect. Dis."},{"key":"2025010608555275000_r22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4049\/immunohorizons.2400013","article-title":"Monophosphoryl lipid A-based adjuvant to promote the immunogenicity of multivalent meningococcal polysaccharide conjugate vaccines","volume":"8","author":"Alugupalli","year":"2024","journal-title":"Immunohorizons"},{"key":"2025010608555275000_r23","doi-asserted-by":"crossref","first-page":"1383476","DOI":"10.3389\/fimmu.2024.1383476","article-title":"A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines","volume":"15","author":"Alugupalli","year":"2024","journal-title":"Front. Immunol."},{"key":"2025010608555275000_r24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ni776","article-title":"Role of antigen receptor affinity in T cell-independent antibody responses in vivo","volume":"3","author":"Shih","year":"2002","journal-title":"Nat. Immunol."},{"key":"2025010608555275000_r25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/ni803","article-title":"Role of BCR affinity in T cell dependent antibody responses in vivo","volume":"3","author":"Shih","year":"2002","journal-title":"Nat. Immunol."},{"key":"2025010608555275000_r26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/intimm\/dxr002","article-title":"Characterization of memory B cells responsible for affinity maturation of anti- (4-hydroxy-3-nitrophenyl)acetyl (NP) antibodies","volume":"23","author":"Nishimura","year":"2011","journal-title":"Int. Immunol."},{"key":"2025010608555275000_r27","doi-asserted-by":"crossref","first-page":"eadd9413","DOI":"10.1126\/sciimmunol.add9413","article-title":"B cell- and T cell-intrinsic regulation of germinal centers by thymic stromal lymphopoietin signaling","volume":"8","author":"Domeier","year":"2023","journal-title":"Sci. Immunol."},{"key":"2025010608555275000_r28","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/ni712","article-title":"Toll-like receptors control activation of adaptive immune responses","volume":"2","author":"Schnare","year":"2001","journal-title":"Nat. Immunol."},{"key":"2025010608555275000_r29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.64.4.625","article-title":"Studies on the sensitization of animals with simple chemical compounds. II","volume":"64","author":"Landsteiner","year":"1936","journal-title":"J. Exp. Med."},{"key":"2025010608555275000_r30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJM199011153232010","article-title":"Evaluating the Haemophilus influenzae type b conjugate vaccine PRP-D","volume":"323","author":"Robbins","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"2025010608555275000_r31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.50.4.533","article-title":"Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens","volume":"50","author":"Avery","year":"1929","journal-title":"J. Exp. Med."},{"key":"2025010608555275000_r32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1084\/jem.171.3.843","article-title":"Biased expression of JH-proximal VH genes occurs in the newly generated repertoire of neonatal and adult mice","volume":"171","author":"Malynn","year":"1990","journal-title":"J. Exp. Med."},{"key":"2025010608555275000_r33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1084\/jem.168.2.589","article-title":"Comparison of the fetal and adult functional B cell repertoires by analysis of VH gene family expression","volume":"168","author":"Jeong","year":"1988","journal-title":"J. Exp. Med."},{"key":"2025010608555275000_r34","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.4049\/jimmunol.1800162","article-title":"IL-7 enables antibody responses to bacterial polysaccharides by promoting B cell receptor diversity","volume":"201","author":"Dickinson","year":"2018","journal-title":"J. Immunol."},{"key":"2025010608555275000_r35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun. Ageing"},{"key":"2025010608555275000_r36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4049\/jimmunol.165.3.1243","article-title":"Age-dependent alterations in the assembly of signal transduction complexes at the site of T cell\/APC interaction","volume":"165","author":"Tamir","year":"2000","journal-title":"J. Immunol."},{"key":"2025010608555275000_r37","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.celrep.2019.10.008","article-title":"Rapid germinal center and antibody responses in non-human primates after a single nanoparticle vaccine immunization","volume":"29","author":"Havenar-Daughton","year":"2019","journal-title":"Cell Rep."},{"key":"2025010608555275000_r38","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"key":"2025010608555275000_r39","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4049\/jimmunol.1900228","article-title":"The pyroptotic cell death effector gasdermin D is activated by gout-associated uric acid crystals but is dispensable for cell death and IL-1\u03b2 release","volume":"203","author":"Rashidi","year":"2019","journal-title":"J. Immunol."},{"key":"2025010608555275000_r40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1172\/JCI200522462","article-title":"MyD88-dependent induction of allergic Th2 responses to intranasal antigen","volume":"115","author":"Piggott","year":"2005","journal-title":"J. Clin. Invest."},{"key":"2025010608555275000_r41","doi-asserted-by":"crossref","first-page":"577823","DOI":"10.3389\/fimmu.2020.577823","article-title":"MPL adjuvant contains competitive antagonists of human TLR4","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Immunol."},{"volume-title":"The Immune System.","year":"2015","author":"Parham","key":"2025010608555275000_r42"},{"key":"2025010608555275000_r43","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41590-018-0156-5","article-title":"Second signals rescue B cells from activation-induced mitochondrial dysfunction and death","volume":"19","author":"Akkaya","year":"2018","journal-title":"Nat. Immunol."},{"key":"2025010608555275000_r44","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1084\/jem.20161955","article-title":"Co-stimulatory function in primary germinal center responses: CD40 and B7 are required on distinct antigen-presenting cells","volume":"214","author":"Watanabe","year":"2017","journal-title":"J. Exp. Med."},{"key":"2025010608555275000_r45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/08916934.2012.749244","article-title":"Regulation of Aicda expression and AID activity","volume":"46","author":"Zan","year":"2013","journal-title":"Autoimmunity"},{"key":"2025010608555275000_r46","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ncomms1769","article-title":"BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-\u03baB pathway","volume":"3","author":"Pone","year":"2012","journal-title":"Nat. Commun."},{"key":"2025010608555275000_r47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2567.2008.02832.x","article-title":"The modulatory effects of lipopolysaccharide-stimulated B cells on differential T-cell polarization","volume":"125","author":"Xu","year":"2008","journal-title":"Immunology"},{"key":"2025010608555275000_r48","doi-asserted-by":"crossref","first-page":"e62622","DOI":"10.1371\/journal.pone.0062622","article-title":"Inefficient TLR4\/MD-2 heterotetramerization by monophosphoryl lipid A","volume":"8","author":"Casella","year":"2013","journal-title":"PLoS One"},{"key":"2025010608555275000_r49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00011-016-0927-0","article-title":"Monophosphoryl lipid A-induced pro-inflammatory cytokine expression does not require CD14 in primary human dendritic cells","volume":"65","author":"Kolanowski","year":"2016","journal-title":"Inflamm. Res."},{"key":"2025010608555275000_r50","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1038\/s41598-018-25367-y","article-title":"Specific features of human monocytes activation by monophosphoryl lipid A","volume":"8","author":"Chentouh","year":"2018","journal-title":"Sci. Rep."},{"key":"2025010608555275000_r51","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1126\/science.1138963","article-title":"The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4","volume":"316","author":"Mata-Haro","year":"2007","journal-title":"Science"},{"key":"2025010608555275000_r52","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"2025010608555275000_r53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.0300-9475.2004.01362.x","article-title":"The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis","volume":"59","author":"Michaelsen","year":"2004","journal-title":"Scand. J. Immunol."},{"key":"2025010608555275000_r54","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/IAI.74.2.1025-1031.2006","article-title":"Correlation of molecular characteristics, isotype, and in vitro functional activity of human antipneumococcal monoclonal antibodies","volume":"74","author":"Baxendale","year":"2006","journal-title":"Infect. Immun."},{"key":"2025010608555275000_r55","doi-asserted-by":"crossref","first-page":"201991","DOI":"10.1098\/rsos.201991","article-title":"A brief review on Group A Streptococcus pathogenesis and vaccine development","volume":"8","author":"Castro","year":"2021","journal-title":"R. Soc. Open Sci."},{"key":"2025010608555275000_r56","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(17)30108-1","article-title":"Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial","volume":"17","author":"Huttner","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"2025010608555275000_r57","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrmicro1662","article-title":"Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road","volume":"5","author":"Levine","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"2025010608555275000_r58","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/ofid\/ofad041","article-title":"Salmonella combination vaccines: moving beyond typhoid","volume":"10","author":"MacLennan","year":"2023","journal-title":"Open Forum Infect. Dis."}],"container-title":["ImmunoHorizons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/8\/8\/527\/60188784\/ih2400040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/8\/8\/527\/60188784\/ih2400040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:57:54Z","timestamp":1736153874000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article\/8\/8\/527\/7848620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.4049\/immunohorizons.2400040","relation":{},"ISSN":["2573-7732"],"issn-type":[{"type":"electronic","value":"2573-7732"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8,1]]}}}